Close Menu

The Next Biotech

NOX Clinic Ready: Phase 1 Study Kicks off in Coming Weeks

Earlier this month, actor and director Ben Stiller publicised the fact he fought (and beat) an aggressive form of prostate cancer in 2014. He states his success over the oft-deadly disease is down to a PSA test that he took at an earlier age than what doctors commonly recommend.

Oct 26, 2016

Positive Phase II Results: DXB on Track to Find Kidney Disease Solution

There could be a light at the end of the tunnel for chronic kidney disease sufferers, suffering from a rare form of the disease known as focal segmental glomerulosclerosis (FSGS). In fact several multi-million dollar companies in the space are dedicated to delivering life changing therapies to people living with chronic kidney disease with significant unmet medical needs.

Oct 10, 2016

MXC Expecting Imminent Medical Cannabis Revenue Deals

As Australia prepares for the legalisation of medicinal marijuana in November – following bipartisan support at a Federal level and a formal decision by the Therapeutic Goods Administration – the future is looking encouraging for medical cannabis company MGC Pharmaceuticals (ASX:MXC).

Oct 6, 2016

CDY Sales Up 72%: $100M Revenue Targets in Place

Calendar year 2016 will go down as a dynamic period of growth in the life of Cellmid (ASX: CDY), a revenue generating life sciences company with lead programs in multiple disease indications and a consumer health business which has just come into its own in the last 12 months.

Sep 14, 2016

Canadian Pot Stocks Light Up the TSX: Is MMJ Next?

While MMJ PhytoTech (ASX:MMJ) has operations all around the globe, for its growing operations it has bunkered down in Canada and already established a solid base there. There are several reasons for this: Canada has a more advanced growing industry than anywhere in the world; its TSX listed medical marijuana stocks are gaining traction on the market and regulations are well and truly opening up.

Aug 30, 2016

DXB Close to Phase 2 Results: Progresses Promising CKD Product

Dimerix (ASX:DXB) has just completed its “pre-IND” consultation with US regulatory body the Food and Drug Administration (FDA) with some encouraging outcomes reported. The big news for DXB is that its intended Phase 3 DMX-200 trial will be positioned as an adjunct therapy and not a fixed dose combination therapy.

Aug 16, 2016

Medical Cannabis Stock MXC Approaching Revenue Uplift?

Having gained regulatory approval to sell its MGC Derma Anti-Aging line of Cannabidiol-based cosmetic products in the US, MGC Pharmaceuticals (ASX:MXC) recently received its first revenues under its exclusive Californian distribution deal. The first year of the deal is expected to net MXC approximately AU$1.76M – a substantial number for this $51.5M capped company that has only really been on the ASX boards for a short amount of time.

Jul 22, 2016

Current Stocks